According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
SBBP has been the topic of several other reports. Oppenheimer reaffirmed a buy rating and set a $6.00 target price on shares of Strongbridge Biopharma in a research report on Wednesday, May 6th. Craig Hallum initiated coverage on Strongbridge Biopharma in a research report on Tuesday, March 3rd. They set a buy rating and a $7.50 target price on the stock. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $8.65.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.03. Strongbridge Biopharma had a negative return on equity of 57.46% and a negative net margin of 181.82%. The company had revenue of $6.67 million for the quarter, compared to analyst estimates of $5.97 million. On average, research analysts forecast that Strongbridge Biopharma will post -0.93 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Barclays PLC grew its stake in Strongbridge Biopharma by 91.5% during the 4th quarter. Barclays PLC now owns 37,077 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 17,718 shares during the last quarter. State Street Corp grew its stake in Strongbridge Biopharma by 6.5% during the 4th quarter. State Street Corp now owns 676,371 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 41,284 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Strongbridge Biopharma by 16.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 34,240 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 4,814 shares during the last quarter. BlackRock Inc. grew its stake in Strongbridge Biopharma by 3.9% during the 1st quarter. BlackRock Inc. now owns 2,060,982 shares of the biotechnology company’s stock valued at $3,895,000 after purchasing an additional 76,865 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in Strongbridge Biopharma by 336.9% during the 4th quarter. Acadian Asset Management LLC now owns 48,849 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 37,669 shares during the last quarter. Institutional investors and hedge funds own 47.56% of the company’s stock.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Recommended Story: What are benefits of a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.